NCT03540199

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer

Withdrawn Phase 2 Last updated 19 October 2020

What this trial tests

Phase 2 trial testing Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer in Advanced Kidney Cancer. Withdrawn.

Timeline

10 April 2018

Primary endpoint
20 May 2020

10 September 2020

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	10 April 2018
Primary completion	20 May 2020
Estimated completion	10 September 2020
Sites	1 location across China

Drugs / interventions tested

• Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer — full drug profile →
• cryotherapy (CRYOTHERAPY) — full drug profile →

Conditions studied

• Advanced Kidney Cancer — all drugs for Advanced Kidney Cancer →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 18 to 75, any sex, with Advanced Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced kidney cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for kidney cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
   Runcie K, Budman DR, John V, Seetharamu N. · · 2018 · cited 120× · PMID 30249178 · DOI 10.1186/s10020-018-0051-4
2. Overcoming the challenges associated with CD3+ T-cell redirection in cancer.
   Singh A, Dees S, Grewal IS. · · 2021 · cited 82× · PMID 33469153 · DOI 10.1038/s41416-020-01225-5
3. Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
   Yakkala C, Chiang CL, Kandalaft L, Denys A, et al · · 2019 · cited 67× · PMID 31608067 · DOI 10.3389/fimmu.2019.02283
4. Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers.
   Bose M, Mukherjee P. · · 2020 · cited 40× · PMID 33167508 · DOI 10.3390/vaccines8040659
5. Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.
   Hushmandi K, Einollahi B, Lee EHC, Sakaizawa R, et al · · 2025 · cited 7× · PMID 39990653 · DOI 10.7150/ijbs.96155
6. Research progress of MUC1 in genitourinary cancers.
   Mao W, Zhang H, Wang K, Geng J, et al · · 2024 · cited 3× · PMID 39491020 · DOI 10.1186/s11658-024-00654-x